Quantum Biopharma Ltd. QNTM

Quantum BioPharma (QNTM) has received FDA clearance of its Investigational New Drug application to advance Lucid-MS into Phase 2 testing for multiple sclerosis. Lucid-MS, the company’s lead candidate, employs a proprietary mechanism distinct from most MS therapies. Phase 1 testing showed Lucid-MS was well tolerated with a favorable safety profile, enabling progression to next-stage trials. With IND approval, Quantum BioPharma can begin patient recruitment and administer the drug under regulatory oversight in a controlled setting. The development underscores Quantum’s focus on neurodegenerative and metabolic disorders and could impact investor sentiment as it moves toward later-stage trials. Advances to Phase 2 after IND approval represent a meaningful regulatory milestone likely to boost sentiment and potential valuation.

Quantum BioPharma Ltd. said its licensee Unbuzzd Wellness Inc. has appointed Michael 'Zappy' Zapolin as chief executive officer to secure financing, pursue a stock exchange listing, and execute a nationwide U.S. rollout of unbuzzd. Zapolin, a Wall Street veteran and entrepreneur, will lead fundraising, brand building and distribution expansion. Unbuzzd is clinically validated as a beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms, backed by a peer‑reviewed study published in 2026; the product is sold online and via ready-to-mix sticks. The distribution plan targets pharmacies, liquor stores, supermarkets, convenience stores, colleges and e-commerce, with a multi‑channel platform. Quantum retains about 19.48% of Unbuzzd and a 7% royalty on sales until $250 million, then 3% in perpetuity. A transition from CEO Richard Buzbuzian is underway; the company says growth opportunities are substantial. Royalty-based revenue from Unbuzzd and a planned US rollout with a new CEO could materially affect Quantum BioPharma's financials and growth trajectory.

Quantum BioPharma (QNTM) is pursuing Lucid-MS, its lead drug candidate, to treat multiple sclerosis by directly inhibiting demyelination through blocking peptidyl arginine deiminase 2 (PAD2). MS affects about one million people in the United States and nearly three million worldwide, with progressive forms remaining hard to treat and no approved therapy reverses neurodegeneration. The company positions Lucid-MS as a novel approach addressing an unmet need in a disease with rising prevalence. The release includes standard forward-looking language and links to its newsroom. Preclinical stage with a novel PAD2 mechanism may influence sentiment and future R&D modestly, pending clinical validation.

Rodman & Renshaw initiates analyst coverage on Quantum BioPharma Ltd. (QNTM) with a BUY rating and US$8 price target. Buy rating and price target from new analyst coverage can lift near-term investor sentiment and trading activity.

Quantum BioPharma Ltd. gains FDA clearance to launch historic clinical trials for multiple sclerosis treatment, addressing a key therapy gap. FDA clearance for historic MS trials marks a pivotal regulatory step likely to drive major shifts in company trajectory and sentiment.

Quantum BioPharma Ltd. (QNTM) obtained FDA clearance to begin clinical trials for a historic multiple sclerosis treatment. FDA clearance to start MS treatment trials marks a major regulatory step that can significantly shift company trajectory and investor sentiment.

Quantum BioPharma advances its myelin-protecting multiple sclerosis therapy amid evolving treatment approaches. Core therapy advancement signals major strategic progress that could reshape company trajectory and investor outlook.

Quantum BioPharma (QNTM) reported lower Q2 expenses and advanced Lucid-MS into Phase 2. Lower Q2 expenses and Phase 2 advancement of Lucid-MS signal improved finances plus major clinical progress for Quantum BioPharma.

Quantum BioPharma Ltd. strengthens equity and liquidity in Q2 2026 as FDA approves Lucid-MS for pivotal Phase 2 clinical trial. FDA approval for Phase 2 trial of Lucid-MS plus equity and liquidity gains signal major regulatory and financial progress for the company.

Quantum BioPharma Ltd. (QNTM) focuses on addressing disability drivers in multiple sclerosis beyond relapse rates. QNTM's focus on disability drivers in multiple sclerosis may improve its positioning in neurological treatments.

Quantum BioPharma Ltd. (QNTM) secured FDA clearance to start its Multiple Sclerosis clinical trial. FDA clearance for Multiple Sclerosis trial marks major regulatory progress that can shift company trajectory and investor sentiment.

Quantum BioPharma (QNTM) received FDA clearance to advance Lucid-MS into Phase 2 clinical trials. FDA clearance advances Lucid-MS to Phase 2 trials, a major regulatory step likely to lift company trajectory and sentiment.

Quantum BioPharma secures FDA clearance to begin a Multiple Sclerosis clinical trial, marking a key regulatory milestone for the company. FDA clearance to start MS trial marks major regulatory progress that can shift company trajectory and investor sentiment.

Quantum BioPharma (QNTM) advances its MS imaging study and reports encouraging preliminary results. Encouraging preliminary MS imaging study results may moderately lift near-term sentiment and valuation for Quantum Biopharma.

Quantum BioPharma executive outlines Lucid-MS development strategy and commercial growth plans. Strategy outline for Lucid-MS signals major product development progress and market expansion moves.

Quantum BioPharma (QNTM) advances a two-pronged strategy targeting brain disorders affecting millions. QNTM advances core R&D on brain disorder treatments with potential to reshape its pipeline and investor outlook.

Quantum BioPharma Ltd. announces intention to settle outstanding debt. Debt settlement directly improves balance sheet and reduces financial obligations.

Quantum BioPharma Ltd. (QNTM) expands clinical development of its neuroprotective therapy. Clinical expansion of neuroprotective therapy marks major strategic progress capable of shifting company trajectory and investor sentiment.

Quantum BioPharma (QNTM) reaches key midpoint milestone in multiple sclerosis imaging study. Midpoint milestone advances MS imaging study in core pipeline.

Quantum BioPharma Ltd. advances its innovative first-in-class patented multiple sclerosis therapy. Patented first-in-class MS therapy development signals major product innovation with potential to shift company trajectory and investor sentiment.

Quantum BioPharma advances novel multiple sclerosis therapy toward Phase 2 trials. Advancing core MS therapy into Phase 2 marks major clinical pipeline progress with direct effects on company trajectory.

Quantum BioPharma Ltd. develops patented first-in-class multiple sclerosis treatment using novel approach. Patented new MS treatment development signals major strategic advance with strong potential to shift company trajectory.

Quantum BioPharma advances its proprietary therapy for multiple sclerosis treatment. Advancing core MS therapy constitutes major strategic progress capable of altering company trajectory.

Quantum BioPharma (QNTM) expands its product pipeline across neurological disorders and wellness markets. Pipeline expansion into neurological and wellness areas supports moderate long-term growth and market positioning.

Quantum BioPharma Ltd. issued a corporate update covering recent operational progress, strategic plans and company developments. Corporate updates deliver operational and strategic details that can moderately sway near-term investor views and trading.

Quantum BioPharma (QNTM) has reached the midpoint enrollment milestone in its multiple sclerosis imaging study. Midpoint enrollment in the MS imaging study marks measurable progress in Quantum BioPharma's core clinical pipeline.

Quantum BioPharma Ltd. (QNTM) has reached the halfway point in patient enrollment for its imaging study conducted with MGH. Halfway enrollment in a clinical imaging study marks incremental research progress that may moderately support future development and market positioning.

Quantum BioPharma Ltd. shares climb as its multiple sclerosis imaging study advances. Advancement of multiple sclerosis imaging study drives share gains and signals incremental development progress for Quantum BioPharma.

Quantum BioPharma reaches key midpoint milestone in imaging study with Massachusetts General Hospital. Midpoint study milestone may lift sentiment and support near-term positioning without assured revenue or product approval.

Quantum Biopharma Ltd. (QNTM) reports strengthened liquidity, reduced cash burn, and disciplined cost management in the first quarter of 2026. Strengthened liquidity and reduced cash burn positively influence financial performance and runway but remain limited in scope without major strategic shifts.